Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Oxytocin PK and Safety in Healthy Females
NCT02542813Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by GSK. Primary endpoints: Number of subjects with adverse events up to 16 weeks, Absolute values and changes over time of haematology up to 20 weeks and 11 more. Started Sep 2015; status: completed.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on NCT02542813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542813.